Clinical–Liver, Pancreas, and Biliary TractDaily Cannabis Use: A Novel Risk Factor of Steatosis Severity in Patients With Chronic Hepatitis C
Section snippets
Patients
Consecutive patients were recruited in a single tertiary care center between May 2003 and June 2006 if they met the following criteria: (1) HCV infection defined by a positive test for anti-HCV antibodies (Ortho HCV 3.0 ELISA test system; Ortho Clinical Diagnostics, Raritan, NJ) with detectable serum HCV RNA (Amplicor HCV 2.0 PCR test system; Roche Molecular Systems, Pleasanton, CA) documented for at least 6 months, (2) available liver biopsy specimen (15 mm or greater, with at least 6 portal
Study Population
Table 1 summarizes baseline characteristics of the overall study population (n = 315). There were 223 men and 92 women with a mean age at liver biopsy of 45.1 ± 10.9 years and an average BMI of 24.8 kg/m2. Ongoing alcohol abuse was reported by 13.3% of patients. Intravenous drug use was the most common route of transmission (44.1%). Genotype distribution showed a predominance of genotype 1 (62.5%), followed by genotype 3 (21.0%). Activity grade ≥A2 and significant fibrosis (≥F2) were found in
Discussion
Control of comorbidities is currently considered a desirable goal in patients with CHC, particularly in difficult-to-treat patients. A large majority of studies have repeatedly shown that steatosis is an independent predictor of liver fibrosis progression in these patients.3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 In addition, steatosis is an established factor of poor response to antiviral therapy, particularly in patients infected with non-3 genotypes.1, 10, 30 In the present study, we
References (42)
- et al.
Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States
J Hepatol
(2004) - et al.
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data
Gastroenterology
(2006) - et al.
The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients
J Hepatol
(2004) - et al.
Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C
Hepatology
(2003) - et al.
Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity
Hepatology
(2001) - et al.
Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol
Hepatology
(2002) The endocannabinoid system: mechanisms behind metabolic homeostasis and imbalance
Am J Med
(2007)- et al.
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
Lancet
(2005) - et al.
Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3
J Hepatol
(2000) - et al.
Drug use and drinking among students in 36 countries
Addict Behav
(2000)
Antifibrogenic role of the cannabinoid receptor CB2 in the liver
Gastroenterology
Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat
Gastroenterology
Hepatitis C virus-induced hepatocellular steatosis
Am J Gastroenterol
Steatosis in chronic hepatitis C: why does it really matter?
Gut
Impact of steatosis on progression of fibrosis in patients with mild hepatitis C
Hepatology
Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C
Hepatology
Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis
Hepatology
Steatosis affects chronic hepatitis C progression in a genotype specific way
Gut
Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis
Gut
Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies
Gut
Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study
Aliment Pharmacol Ther
Cited by (160)
Recreational cannabis use: French perspective of adverse effects
2023, Cannabis Use, Neurobiology, Psychology, and TreatmentEASL Recognition Award Recipient 2022: Dr. Sophie Lotersztajn
2022, Journal of HepatologyMedical cannabis as an alternative therapeutics for Parkinsons’ disease: Systematic review
2020, Complementary Therapies in Clinical PracticeCitation Excerpt :In addition, a cautionary note is recommended in patients with cardiovascular disease [30]. Cannabinoids may promote fatty liver disease and should be avoided in patients with chronic hepatitis C [34]. In patients with impaired liver or kidney function, the effect of THC and CBD may be increased or prolonged.
Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients
2019, Progress in Neuro-Psychopharmacology and Biological PsychiatryThe end of convergence in developmental patterns of frequent marijuana use from ages 18 to 30: An analysis of cohort change from 1976–2016
2018, Drug and Alcohol DependenceCitation Excerpt :While 4%–5% may appear to represent only a small number of individuals, based on U.S. Census Bureau estimates, 4.5% of those who were 30 years of age during 2008–2016 is estimated to be approximately 1.7 million individuals (U.S. Census Bureau, 2004, 2014). As noted previously, those who use marijuana frequently are at increased risk for addiction, cognitive impairment, and other health concerns (Becker et al., 2014; Gordon et al., 2013; Volkow et al., 2014; Whitlow et al., 2004; Hézode et al., 2008; Ishida et al., 2008), and the highest health risks are associated with chronic use that extends into age 30 and beyond (Auer et al., 2015; Epstein et al., 2015; Terry-McElrath et al., 2017). Results from the current study indicate that the number of individuals at high risk for such negative health outcomes due to frequent marijuana use at age 30 has increased markedly among recent cohorts.
The Mexican consensus on the treatment of hepatitis C
2018, Revista de Gastroenterologia de Mexico
- 1
A.M. and S.L. hold a patent in common with Sanofi-Aventis.
- 2
C.H., E.S.Z., F.R.-T., C.C., A.H., M.B.-A., F.M., and J.-M.P. report no conflict of interest.